These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
520 related articles for article (PubMed ID: 33714753)
1. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody. Terry JS; Anderson LB; Scherman MS; McAlister CE; Perera R; Schountz T; Geiss BJ Virology; 2021 Jun; 558():28-37. PubMed ID: 33714753 [TBL] [Abstract][Full Text] [Related]
2. Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies. Terry JS; Anderson LB; Scherman MS; McAlister CE; Perera R; Schountz T; Geiss BJ bioRxiv; 2020 Sep; ():. PubMed ID: 32908982 [TBL] [Abstract][Full Text] [Related]
3. Preparation of highly specific monoclonal antibodies against SARS-CoV-2 nucleocapsid protein and the preliminary development of antigen detection test strips. Xie C; Ding H; Ding J; Xue Y; Lu S; Lv H J Med Virol; 2022 Apr; 94(4):1633-1640. PubMed ID: 34904253 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses. Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329 [TBL] [Abstract][Full Text] [Related]
5. Design and Development of an Antigen Test for SARS-CoV-2 Nucleocapsid Protein to Validate the Viral Quality Assurance Panels. Ray P; Ledgerwood-Lee M; Brickner H; Clark AE; Garretson A; Graham R; Van Zant W; Carlin AF; Aronoff-Spencer ES Viruses; 2024 Apr; 16(5):. PubMed ID: 38793544 [TBL] [Abstract][Full Text] [Related]
6. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Vojdani A; Vojdani E; Kharrazian D Front Immunol; 2020; 11():617089. PubMed ID: 33584709 [TBL] [Abstract][Full Text] [Related]
7. N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2. Yue L; Cao H; Xie T; Long R; Li H; Yang T; Yan M; Xie Z J Med Virol; 2021 Mar; 93(3):1732-1738. PubMed ID: 32965677 [TBL] [Abstract][Full Text] [Related]
8. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. Kang S; Yang M; He S; Wang Y; Chen X; Chen YQ; Hong Z; Liu J; Jiang G; Chen Q; Zhou Z; Zhou Z; Huang Z; Huang X; He H; Zheng W; Liao HX; Xiao F; Shan H; Chen S Nat Commun; 2021 May; 12(1):2697. PubMed ID: 33976229 [TBL] [Abstract][Full Text] [Related]
9. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies. Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184 [TBL] [Abstract][Full Text] [Related]
10. Toolkit for Quickly Generating and Characterizing Molecular Probes Specific for SARS-CoV-2 Nucleocapsid as a Primer for Future Coronavirus Pandemic Preparedness. Sherwood LJ; Hayhurst A ACS Synth Biol; 2021 Feb; 10(2):379-390. PubMed ID: 33534552 [TBL] [Abstract][Full Text] [Related]
11. Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study. Schaffner A; Risch L; Weber M; Thiel S; Jüngert K; Pichler M; Wohlwend N; Lung T; Ritzler M; Hillmann D; Copeland S; Renz H; Paprotny M; Risch M Clin Chem Lab Med; 2020 Nov; 59(2):e49-e51. PubMed ID: 33554502 [No Abstract] [Full Text] [Related]
13. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice. He J; Huang JR; Zhang YL; Zhang J J Med Virol; 2021 Apr; 93(4):1923-1925. PubMed ID: 33386773 [TBL] [Abstract][Full Text] [Related]
14. Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis. Zhang L; Zheng B; Gao X; Zhang L; Pan H; Qiao Y; Suo G; Zhu F Front Immunol; 2020; 11():595970. PubMed ID: 33281824 [TBL] [Abstract][Full Text] [Related]
15. IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients. Yang L; Xu Q; Yang B; Li J; Dong R; Da J; Ye Z; Xu Y; Zhou H; Zhang X; Liu L; Zha Y; Yu F BMC Microbiol; 2021 Dec; 21(1):351. PubMed ID: 34922455 [TBL] [Abstract][Full Text] [Related]
16. Dimerization of SARS-CoV-2 nucleocapsid protein affects sensitivity of ELISA based diagnostics of COVID-19. Khan WH; Khan N; Mishra A; Gupta S; Bansode V; Mehta D; Bhambure R; Ansari MA; Das S; Rathore AS Int J Biol Macromol; 2022 Mar; 200():428-437. PubMed ID: 35051498 [TBL] [Abstract][Full Text] [Related]
17. Selection and characterization of human scFvs targeting the SARS-CoV-2 nucleocapsid protein isolated from antibody libraries of COVID-19 patients. Lisi S; Malerba F; Quaranta P; Florio R; Vitaloni O; Monaca E; Bruni Ercole B; Bitonti AR; Del Perugia O; Mignanelli M; Perrera P; Sabbatella R; Raimondi F; Piazza CR; Moles A; Alfano C; Pistello M; Cattaneo A Sci Rep; 2024 Jul; 14(1):15864. PubMed ID: 38982108 [TBL] [Abstract][Full Text] [Related]
18. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Smits VAJ; Hernández-Carralero E; Paz-Cabrera MC; Cabrera E; Hernández-Reyes Y; Hernández-Fernaud JR; Gillespie DA; Salido E; Hernández-Porto M; Freire R Biochem Biophys Res Commun; 2021 Mar; 543():45-49. PubMed ID: 33515911 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline. Bolotin S; Tran V; Osman S; Brown KA; Buchan SA; Joh E; Deeks SL; Allen VG J Infect Dis; 2021 Apr; 223(8):1334-1338. PubMed ID: 33400794 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B Front Immunol; 2021; 12():614436. PubMed ID: 33790892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]